狂犬病
病毒学
免疫系统
狂犬病病毒
狂犬病疫苗
接种疫苗
信使核糖核酸
鸭胚疫苗
中和抗体
抗体
免疫学
病毒
生物
基因
生物化学
作者
Jinrong Long,Changxiao Yu,Yiming Cao,Yiqi Miao,Huisheng Sun,Zhen Zhang,Jierui Mai,Xin Wang,Yingying Mao,Hongwei Li,Jing Yang,Shengqi Wang
出处
期刊:Nano Today
[Elsevier]
日期:2023-12-01
卷期号:53: 102038-102038
标识
DOI:10.1016/j.nantod.2023.102038
摘要
Rabies is a fatal viral disease caused by the rabies virus (RABV), with a case fatality rate in humans of almost 100%. Vaccinations are the most effective method of preventing and controlling rabies. Currently, the most widely used vaccines are all inactivated vaccines, which require considerable time and money to produce. A messenger RNA (mRNA)-based vaccine is a rapid and versatile platform for relatively easy vaccine production on a large scale. Here, we developed a lipid nanoparticle-encapsulated mRNA (mRNA-LNP) vaccine encoding a rabies virus glycoprotein (RABV-G). Two doses of the mRNA-B-LNP vaccine were highly immunogenic and induced robust immune responses and robust Tfh and GC B cellular response as well as a Th1-biased cellular immune response in mice and protected mice against the rabies virus. A single dose of the mRNA-B-LNP vaccine induced a rapid and long-term protective antibody response in mice. Compared to the inactivated vaccine, a single dose of the mRNA-B-LNP vaccine induced higher neutralizing antibody titers in dogs, and two doses of the mRNA-B-LNP vaccine induced a durable humoral response in dogs. Additionally, the mRNA-B-LNP vaccine as a liquid formulation can be stored at 2 − 8 °C for 2 months.
科研通智能强力驱动
Strongly Powered by AbleSci AI